A Study of Leuprorelin 1-Month (4-Week) Formulation in Children With Central Precocious Puberty
Recruiting
Phase 4
Interventional Study
Central Precocious Puberty
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- Up to 10
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 43 (estimated)
- Sponsor
- LG Chem · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
A Single-Arm, Open-Label, Multicenter, Prospective Clinical Study to Evaluate the Effectiveness and Safety of Leuprorelin 1-Month (4-Week) Formulation Administered for 24 Months in Children with Central Precocious Puberty
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Tanner stage =\>2
2. Girls younger than 9 years old, boys younger than 10 years old
3. Subjects who are diagnosed with central precocious puberty (CPP)
Exclusion Criteria:
1. GnRH-independent precocious puberty, incomplete precocious puberty, progressive brain tumors, pitui…
Contacts